Neuroprotective role of melatonin in methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Ali
S F
SF
Neurochemistry Laboratory, National Center for Toxicological Research/FDA, Jefferson, Arkansas 72079-9502, USA. sali@nctr.fda.gov
Martin
J L
JL
Black
M D
MD
Itzhak
Y
Y
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000037:antagonists & inhibitors; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents; D004353:Drug Evaluation, Preclinical; D005334:Fever / Q000139:chemically induced; D016166:Free Radical Scavengers / Q000494:pharmacology*; D008550:Melatonin / Q000494:pharmacology*; D008694:Methamphetamine / Q000037:antagonists & inhibitors; D051379:Mice; D018696:Neuroprotective Agents / Q000494:pharmacology*
D015259:Dopamine Agents; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D008694:Methamphetamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008550:Melatonin; D004298:Dopamine